News

• FDA approval for schizophrenia and HIV generics from Zydus Cadila and Lupin
• Zydus Cadila and Sandoz generics approvals in North America
• EMA recommends approval of abiraterone and ioflupane (123I) generics
• Tentative US approval for Symbicort generic

Research

• Non-profit generics manufacturers in the US reduce foreign dependence
• More out-of-pocket costs for US patients with rising prescription drug prices
• Difficult-to-make drugs meet US quality standards
• New in vitro–in vivo simulations predict generic bioequivalence

General

• Use of generics increases during the COVID-19 pandemic in Mexico
• COVID-19 IP waivers could lead to global pharma patent changes
• COVID-19 favipiravir treatment production opens up in Thailand
• Generics in India

News

• FDA accepts application for Lupin’s pegfilgrastim biosimilar
• Trastuzumab emtansine ‘similar biologic’ Ujvira launched in India
• Clinical trials for aflibercept biosimilars
• Canada approves five adalimumab biosimilars in last six months

Research

• Prices for arthritis biologicals in Latin America
• New data on adalimumab biosimilars from Samsung Bioepis and Boehringer Ingelheim
• Positive phase III results for tocilizumab biosimilar BAT1806
• Efficacy and safety of Yuflyma vs reference adalimumab in rheumatoid arthritis

General

• The role of the patient in treatments with biosimilars in Argentina
• US Supreme Court rejects Enbrel patent challenge from Sandoz
• Biosimilar pipelines for South Korean firms: Celltrion and Samsung Bioepis
• Biosimilar pipelines for South Korean firms: Chong Kun Dang, DM Bio and HK inno.N

• Non‐Biological Complex Drugs
• Country Focus
• Guidelines

• Policies & Legislation
• Reports
• Pharma News

• Conferences
• Sponsored Links
• Sponsored Articles